Cariello, M.; Zerlotin, R.; Pasculli, E.; Piccinin, E.; Peres, C.; Porru, E.; Roda, A.; Gadaleta, R.M.; Moschetta, A.
Intestinal FXR Activation via Transgenic Chimera or Chemical Agonism Prevents Colitis-Associated and Genetically-Induced Colon Cancer. Cancers 2022, 14, 3081.
https://doi.org/10.3390/cancers14133081
AMA Style
Cariello M, Zerlotin R, Pasculli E, Piccinin E, Peres C, Porru E, Roda A, Gadaleta RM, Moschetta A.
Intestinal FXR Activation via Transgenic Chimera or Chemical Agonism Prevents Colitis-Associated and Genetically-Induced Colon Cancer. Cancers. 2022; 14(13):3081.
https://doi.org/10.3390/cancers14133081
Chicago/Turabian Style
Cariello, Marica, Roberta Zerlotin, Emanuela Pasculli, Elena Piccinin, Claudia Peres, Emanuele Porru, Aldo Roda, Raffaella Maria Gadaleta, and Antonio Moschetta.
2022. "Intestinal FXR Activation via Transgenic Chimera or Chemical Agonism Prevents Colitis-Associated and Genetically-Induced Colon Cancer" Cancers 14, no. 13: 3081.
https://doi.org/10.3390/cancers14133081
APA Style
Cariello, M., Zerlotin, R., Pasculli, E., Piccinin, E., Peres, C., Porru, E., Roda, A., Gadaleta, R. M., & Moschetta, A.
(2022). Intestinal FXR Activation via Transgenic Chimera or Chemical Agonism Prevents Colitis-Associated and Genetically-Induced Colon Cancer. Cancers, 14(13), 3081.
https://doi.org/10.3390/cancers14133081
